Outlook Therapeutics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell OTLK and other ETFs, options, and stocks.

About OTLK

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF.

CEO

C. Russell Trenary

CEOC. Russell Trenary

Employees

Employees24

Headquarters

Iselin, New Jersey

HeadquartersIselin, New Jersey

Founded

2010

Founded2010

Employees

Employees24

OTLK Key Statistics

Market cap

181.96M

Market cap181.96M

Price-Earnings ratio

-2.12

Price-Earnings ratio-2.12

Dividend yield

—

Dividend yield—

Average volume

226.93K

Average volume226.93K

High today

$8.48

High today$8.48

Low today

$8.14

Low today$8.14

Open price

$8.22

Open price$8.22

Volume

120.59K

Volume120.59K

52 Week high

$40.60

52 Week high$40.60

52 Week low

$4.00

52 Week low$4.00

Analyst ratings

100%

of 7 ratings

Buy

100%

Hold

Sell

Outlook Therapeutics

Why Robinhood?

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF. Show more

OTLK Key Statistics

Analyst ratings

100%

Outlook Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of ONS-5010/LYTENAVA. Its pipeline includes unmet patient needs, repackaged IV bevacizumab, and anti-VEGF.